SCHEMBL1415693

SCHEMBL1415693

Cc1ccc(Oc2ccnc(N(C)CCOc3ccc(C=O)cc3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.51
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 3/20 0.39
HPGD P15428 1/20 0.39
KCNH2 Q12809 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
GAA P10253 1/20 0.37
GBA1 P04062 1/20 0.37
PKM P14618 2/20 0.36
HTT P42858 1/20 0.36
CYP2A6 P11509 1/20 0.36
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1415700 0.91 LTA4H (0.46) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1415440 0.91 ALDH1A1 (0.41) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL6767013 0.91 ESR1 (0.45) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1415608 0.90 ALDH1A1 (0.50) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1415400 0.90 ALDH1A1 (0.41) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1415480 0.89 SMN1; SMN2 (0.54) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1415752 0.88 TYR (0.40) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1415791 0.88 ALDH1A3 (0.47) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1415513 0.88 ALDH1A1 (0.44) KDM4EALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL1415512 0.81 PPARG (0.48) KDM4EALDH1A1SMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490360-B1 THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARM CORP (KR) 2011-03-16 EP disclosed
EP-1490360-A4 THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARM CORP (KR) 2006-07-05 EP disclosed
EP-1490360-A1 THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2004-12-29 EP disclosed
US-20040122031-A1 Thiazolidinedione and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2004-06-24 US disclosed
WO-2003080605-A1 THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122031-A1 Thiazolidinedione and pharmaceutical composition comprising the same GLP1R, PPARD, SLC5A1 KDM4E 3922/4885ALDH1A1 196/4885LMNA 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.